Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib vs Capecitabine Maintenance in Advanced Gastric Cancer
NCT03889626Phase 3Unknown
- Sponsor
- Fudan University
- Start
- Mar 2019
- Primary completion
- Mar 2022
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
01
Overview
Phase 3, randomised, open-label trial in gastric cancer (GC) comparing Apatinib, Capecitabine and Observation (3 arms). Primary endpoint: Progression Free Survival. Status: unknown.
02
Drugs
Rivoceranibcapecitabine
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03889626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03889626.